Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Net Income towards Common Stockholders: 2010-2025

Historic Net Income towards Common Stockholders for Iovance Biotherapeutics (IOVA) over the last 9 years, with Sep 2025 value amounting to -$91.3 million.

  • Iovance Biotherapeutics' Net Income towards Common Stockholders fell 9.23% to -$91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$397.7 million, marking a year-over-year increase of 2.99%. This contributed to the annual value of -$372.2 million for FY2024, which is 16.18% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Net Income towards Common Stockholders stood at -$91.3 million for Q3 2025, which was up 18.28% from -$111.7 million recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Net Income towards Common Stockholders peaked at -$78.6 million during Q4 2024, and registered a low of -$116.4 million during Q4 2023.
  • Its 3-year average for Net Income towards Common Stockholders is -$103.2 million, with a median of -$107.4 million in 2023.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first spiked by 32.47% in 2024, then fell by 15.05% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$116.4 million in 2023, then surged by 32.47% to -$78.6 million in 2024, then declined by 9.23% to -$91.3 million in 2025.
  • Its last three reported values are -$91.3 million in Q3 2025, -$111.7 million for Q2 2025, and -$116.2 million during Q1 2025.